ArticleZeitschrift fur Gastroenterologie2026
Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's disease.
Jagoda Pokryszka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.